Bausch + Lomb Reports Strong Q1 2026 Results with Significant Profitability and Cash Flow Improvement
summarizeSummary
Bausch + Lomb reported robust first-quarter 2026 financial results, showcasing significant improvements in revenue, operating income, and cash flow from operations, alongside favorable legal outcomes and debt management.
check_boxKey Events
-
Strong Revenue Growth
Total revenues increased by 9% to $1,244 million in Q1 2026, compared to $1,137 million in Q1 2025. On a constant currency basis, revenue growth was 6%, driven by all three segments: Vision Care (+8%), Pharmaceuticals (+14%), and Surgical (+7%).
-
Significant Profitability Improvement
The company swung from an operating loss of $83 million in Q1 2025 to an operating income of $33 million in Q1 2026, a $116 million improvement. Net loss attributable to Bausch + Lomb Corporation also significantly narrowed from $212 million to $71 million.
-
Positive Cash Flow from Operations
Cash flow from operating activities turned positive, providing $32 million in Q1 2026, a notable improvement from using $25 million in Q1 2025.
-
Debt Refinancing and Liquidity Enhancement
Bausch + Lomb completed a $2,802 million term loan refinancing in January 2026, reducing its weighted average interest rate from 7.70% to 7.43%. The company also entered a new financing arrangement to sell receivables, generating $5 million in Q1 2026 and an additional $21 million in April 2026, enhancing liquidity.
auto_awesomeAnalysis
Bausch + Lomb's Q1 2026 results demonstrate a substantial operational turnaround, moving from an operating loss to a significant operating income and generating positive cash flow from operations. This improvement is driven by solid revenue growth across all segments and effective cost management. The successful refinancing of debt and positive resolutions in several key legal proceedings further strengthen the company's financial position and reduce future uncertainties. Investors should view these results as a strong indicator of improving fundamentals and financial health.
At the time of this filing, BLCO was trading at $15.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $10.45 to $18.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.